T Gambichler1, S Mohtezebsade2, U Wieland3, S Silling3, A-K Höh2, M Dreißigacker2, J Schaller4, H-J Schulze5, F Oellig6, A Kreuter7, E Stockfleth2, M Stücker2, F G Bechara2, J C Becker8. 1. Department of Dermatology, Skin Cancer Center, Ruhr-University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany. t.gambichler@klinikum-bochum.de. 2. Department of Dermatology, Skin Cancer Center, Ruhr-University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany. 3. National Reference Center for Papilloma- and Polyomaviruses, Institute of Virology, University of Cologne, Cologne, Germany. 4. Dermatopathology Duisburg, Duisburg, Germany. 5. Department of Dermatology and Dermato-Histo-Pathology, Skin Cancer Center, Fachklinik Hornheide, Münster, Germany. 6. Institute for Pathology, Mülheim/Ruhr, Germany. 7. Department of Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Hospital Oberhausen, Oberhausen, Germany. 8. Translational Skin Cancer Research, DKTK Partner Site Essen/Düsseldorf, West German Cancer Center, Dermatology, University Duisburg-Essen, Essen, Germany.
Abstract
BACKGROUND: It has recently been reported that atonal homolog 1 (ATOH1) gene is down-regulated in Merkel cell carcinoma (MCC) and thus may represent a tumor suppressor gene. OBJECTIVES: We aimed to test for ATOH1 gene mutations and expression levels in MCC tissues and cell lines. METHODS: Genomic DNA isolation and amplification via PCR was successfully performed in 33 MCCs on formalin-fixed paraffin-embedded tissue and three MCC cell lines, followed by Sanger sequencing of the whole ATOH1 gene to detect genomic aberrations. ATOH1 mRNA levels were determined by RT-PCR. Immunohistochemistry of ATOH1 was performed to quantify protein expression in tumor samples and cell lines. RESULTS: Neither in any of the 33 MCC tissue samples nor in the three cell lines ATOH1 mutations were present. ATOH1 was expressed in all lesions, albeit at different expression levels. Univariate analysis revealed that the total immunohistology score significantly correlated with the occurrence of tumor relapse (r = 0.57; P = 0.0008). This notion was confirmed in multivariate analysis suggesting that ATOH1 expression is a potential independent predictor for tumor relapse in MCC patients (P = 0.028). MCC-related death also correlated with ATOH1 expression (r = 0.4; P = 0.025); however, ATOH1 expression did not retain its predictive value in the regression model. CONCLUSIONS: In contrast to anecdotal reports ATOH1 expression is not lost by genetic alterations in MCC. However, protein expression of ATOH1 is increased in advanced MCC indicating that ATOH1 is involved in MCC progression.
BACKGROUND: It has recently been reported that atonal homolog 1 (ATOH1) gene is down-regulated in Merkel cell carcinoma (MCC) and thus may represent a tumor suppressor gene. OBJECTIVES: We aimed to test for ATOH1 gene mutations and expression levels in MCC tissues and cell lines. METHODS: Genomic DNA isolation and amplification via PCR was successfully performed in 33 MCCs on formalin-fixed paraffin-embedded tissue and three MCC cell lines, followed by Sanger sequencing of the whole ATOH1 gene to detect genomic aberrations. ATOH1 mRNA levels were determined by RT-PCR. Immunohistochemistry of ATOH1 was performed to quantify protein expression in tumor samples and cell lines. RESULTS: Neither in any of the 33 MCC tissue samples nor in the three cell lines ATOH1 mutations were present. ATOH1 was expressed in all lesions, albeit at different expression levels. Univariate analysis revealed that the total immunohistology score significantly correlated with the occurrence of tumor relapse (r = 0.57; P = 0.0008). This notion was confirmed in multivariate analysis suggesting that ATOH1 expression is a potential independent predictor for tumor relapse in MCC patients (P = 0.028). MCC-related death also correlated with ATOH1 expression (r = 0.4; P = 0.025); however, ATOH1 expression did not retain its predictive value in the regression model. CONCLUSIONS: In contrast to anecdotal reports ATOH1 expression is not lost by genetic alterations in MCC. However, protein expression of ATOH1 is increased in advanced MCC indicating that ATOH1 is involved in MCC progression.
Authors: J Helen Leonard; Anthony L Cook; Mireille Van Gele; Glen M Boyle; Kelly J Inglis; Frank Speleman; Richard A Sturm Journal: Int J Cancer Date: 2002-09-10 Impact factor: 7.396
Authors: Harri Sihto; Heli Kukko; Virve Koljonen; Risto Sankila; Tom Böhling; Heikki Joensuu Journal: J Natl Cancer Inst Date: 2009-06-17 Impact factor: 13.506
Authors: Kenneth Daily; Amy Coxon; Jonathan S Williams; Chyi-Chia R Lee; Daniel G Coit; Klaus J Busam; Isaac Brownell Journal: J Invest Dermatol Date: 2014-12-18 Impact factor: 8.551
Authors: Wouter Bossuyt; Avedis Kazanjian; Natalie De Geest; Sofie Van Kelst; Gert De Hertogh; Karel Geboes; Greg P Boivin; Judith Luciani; Francois Fuks; Marinee Chuah; Thierry VandenDriessche; Peter Marynen; Jan Cools; Noah F Shroyer; Bassem A Hassan Journal: PLoS Biol Date: 2009-02-24 Impact factor: 8.029
Authors: Masahiro Shuda; Anna Guastafierro; Xuehui Geng; Yoko Shuda; Stephen M Ostrowski; Stefan Lukianov; Frank J Jenkins; Kord Honda; Stephen M Maricich; Patrick S Moore; Yuan Chang Journal: PLoS One Date: 2015-11-06 Impact factor: 3.240
Authors: Jürgen C Becker; Andreas Stang; Axel Zur Hausen; Nicole Fischer; James A DeCaprio; Richard W Tothill; Rikke Lyngaa; Ulla Kring Hansen; Cathrin Ritter; Paul Nghiem; Christopher K Bichakjian; Selma Ugurel; David Schrama Journal: Cancer Immunol Immunother Date: 2017-11-30 Impact factor: 6.968
Authors: Alexis Harold; Yutaka Amako; Junichi Hachisuka; Yulong Bai; Meng Yen Li; Linda Kubat; Jan Gravemeyer; Jonathan Franks; Julia R Gibbs; Hyun Jung Park; Elena Ezhkova; Jürgen C Becker; Masahiro Shuda Journal: Proc Natl Acad Sci U S A Date: 2019-09-16 Impact factor: 11.205
Authors: Benjamin Sundqvist; Harri Sihto; Maria von Willebrand; Tom Böhling; Virve Koljonen Journal: Virchows Arch Date: 2021-07-31 Impact factor: 4.064